This study suggests a novel role of cellular differentiation status and CD38 expression on acquisition of BCR-ABL mutations, and the potential therapeutic use of ATRA to inhibit CML acquired resistance to tyrosine kinase inhibitors. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.